• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Arcturus Therapeutics Holdings Inc.

    7/17/24 5:27:11 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARCT alert in real time by email
    S-8 1 e663719_s8-arct.htm

     

     

    As filed with the Securities and Exchange Commission on July 17, 2024

     

    Registration No. 333-                    

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

      

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

      

    ARCTURUS THERAPEUTICS HOLDINGS INC.

    (Exact name of Registrant as specified in its charter)

      

    Delaware   32-0595345
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number)

      

    10628 Science Center Drive, Suite 250

    San Diego, California 92121

    (858) 900-2660

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    ARCTURUS THERAPEUTICS HOLDINGS INC. 2019 OMNIBUS EQUITY INCENTIVE PLAN, as amended

    (Full title of the plan)

     

    Joseph E. Payne

    Chief Executive Officer

    Arcturus Therapeutics Holdings Inc.

    10628 Science Center Drive, Suite 250

    San Diego, California 92121

    (Name and address of agent for service)

     

    (858) 900-2660

    (Telephone number, including area code, of agent for service)

      

    Copies to:

    Dentons US LLP

    1221 Avenue of the Americas

    New York, New York 10020

    Jeffrey A. Baumel, Esq.  

    Grant Levine, Esq.

      

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐   Accelerated filer   ☒
           
    Non-accelerated filer   ☐   Smaller reporting company   ☐
           
            Emerging growth company   ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐

     

     

     

     

    EXPLANATORY NOTE

     

    Arcturus Therapeutics Holdings Inc., a Delaware corporation (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering an additional 2,000,000 shares of its common stock, issuable to eligible persons under the Amended and Restated 2019 Omnibus Equity Incentive Plan (as amended, the “2019 Plan”), which shares are in addition to the shares registered on the Registrant’s registration statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on June 21, 2019 (File No. 333-232272), the registration statement on Form S-8 filed with the Commission on August 5, 2020 (File No. 333-240397), and the registration statement on Form S-8 filed with the Commission on June 30, 2022 (File No. 333-265925) (together, the “Prior Registration Statements”).

     

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E (“General Instruction E”) to Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), regarding Registration of Additional Securities. Pursuant to General Instruction E, the contents of the Prior Registration Statements, to the extent relating to the registration of common stock issuable under the 2019 Plan, are incorporated herein by reference and made part of this Registration Statement, except to the extent supplemented, amended and superseded by the information set forth herein.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    The following documents filed with the Commission by the Registrant pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are hereby incorporated by reference in this registration statement:

     

    (a)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Commission on March 14, 2024;
    (b)The Registrant’s Quarterly Report on Form 10-Q for the period ended March 31, 2024 filed with the Commission on May 8, 2024;
    (c)The Registrant’s Current Reports on Form 8-K filed with the Commission on February 23, 2024, April 5, 2024, June 14, 2024, and June 24, 2024; and
    (d)The description of the Registrant’s common stock in the Current Report on Form 8-K12B filed with the SEC on June 14, 2019.

     

     

     

     

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this registration statement (except for any portions of the Registrant’s current reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission) and prior to the filing of a post-effective amendment to this registration statement indicating that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date of filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Item 8. Exhibits

     

    Exhibit
    Number
      Documents
    4.1   Certificate of Incorporation of Arcturus Therapeutics Holdings Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-3 (File No. 333-238139), filed with the SEC on May 8, 2020)
    4.2   Bylaws of Arcturus Therapeutics Holdings Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-3 (File No. 333-238139), filed with the SEC on May 8, 2020)
    5.1*   Opinion of Dentons US LLP
    23.1*   Consent of Independent Registered Public Accounting Firm
    23.2*   Consent of Dentons US LLP is contained in Exhibit 5.1 to this Registration Statement.
    24.1*   Power of Attorney is contained on the signature page.
    99.1*   Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended
    107*   Filing Fee Table

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on July 17, 2024.

     

      ARCTURUS THERAPEUTICS HOLDINGS INC.
         
      By:  

    /s/ Joseph E. Payne

          Joseph E. Payne
      Title:   Chief Executive Officer

      

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of Arcturus Therapeutics Holdings Inc., hereby severally constitute and appoint Joseph E. Payne and Dr. Padmanabh Chivukula, and each of them individually, our true and lawful attorney to sign for us and in our names in the capacities indicated below any and all amendments or supplements, including any post-effective amendments, to this Registration Statement on Form S-8 and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming our signatures to said amendments to this Registration Statement signed by our said attorney and all else that said attorney may lawfully do and cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated:

     

    Signature   Title   Date
         

    /s/ Joseph E. Payne

    Joseph E. Payne

     

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      July 17, 2024
         

    /s/ Dr. Padmanabh Chivukula

    Dr. Padmanabh Chivukula

     

    Chief Scientific Officer

    Chief Operating Officer and Secretary

      July 17, 2024
         

    /s/ Dr. Peter Farrell

    Dr. Peter Farrell

      Chairman of the Board   July 17, 2024
         

    /s/ Andy Sassine

    Andy Sassine

     

    Chief Financial Officer, Director

    (principal financial officer)

      July 17, 2024
         

    /s/ Dr. Magda Marquet

    Dr. Magda Marquet

      Director   July 17, 2024
         

    /s/ James Barlow

    James Barlow

      Director   July 17, 2024
         

    /s/ Dr. Edward Holmes

    Dr. Edward Holmes

      Director   July 17, 2024
             

    /s/ Dr. Jing L. Marantz

      Director   July 17, 2024
    Dr. Jing L. Marantz    
         

    /s/ Dr. John Markels

    Dr. John Markels

      Director   July 17, 2024
             
    /s/ Dr. Moncef Slaoui   Director   July 17, 2024
    Dr. Moncef Slaoui        

     

     

     

    Get the next $ARCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARCT

    DatePrice TargetRatingAnalyst
    1/23/2026$20.00Buy
    Roth Capital
    10/24/2025$12.00Buy → Neutral
    H.C. Wainwright
    10/23/2025$12.00Buy → Neutral
    Citigroup
    10/22/2025Buy → Neutral
    Guggenheim
    9/4/2025$60.00Buy
    H.C. Wainwright
    5/28/2025$32.00Sector Outperform
    Scotiabank
    1/28/2025$41.00Buy
    BTIG Research
    8/12/2024$70.00Outperform
    Leerink Partners
    More analyst ratings

    $ARCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Controller Roberts Joseph

    4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    12/19/25 5:22:23 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer & COO Chivukula Pad

    4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    12/19/25 5:21:54 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and CEO Payne Joseph E

    4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    12/19/25 5:21:26 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcturus Therapeutics Holdings Inc.

    SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

    2/3/26 11:27:14 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcturus Therapeutics Holdings Inc.

    SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

    1/8/26 8:12:44 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Arcturus Therapeutics Holdings Inc.

    S-3 - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

    12/30/25 4:00:40 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Arcturus Therapeutics with a new price target

    Roth Capital initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $20.00

    1/23/26 8:16:17 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Arcturus Therapeutics from Buy to Neutral and set a new price target of $12.00

    10/24/25 8:56:54 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics downgraded by Citigroup with a new price target

    Citigroup downgraded Arcturus Therapeutics from Buy to Neutral and set a new price target of $12.00

    10/23/25 7:42:08 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Sassine Andy bought $20,499 worth of shares (1,238 units at $16.56), increasing direct ownership by 0.56% to 221,764 units (SEC Form 4)

    4/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    8/20/25 4:01:44 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Sassine Andy decreased direct ownership by 0.56% to 221,764 units (SEC Form 4)

    4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    8/19/25 4:05:30 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 5:15 p.m. Pacific Time. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRN

    1/8/26 5:30:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics to Attend Upcoming Investor Conference

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conference: Piper Sandler 37th Annual Healthcare Conference (Fireside Chat) Tuesday, December 2, 2025 (12:30 p.m. ET) About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa

    11/24/25 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

    Encouraging CF interim Phase 2 data support continued and expanded trial design 12-week safety and preliminary efficacy study in up to 20 CF participants planned to start H1 2026 Additional cost reductions planned in fourth quarter to extend cash runway Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the third quarter ended September 30, 2025, and provided corporate updates. "We were pleased to share the initi

    11/10/25 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Financials

    Live finance-specific insights

    View All

    Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

    Encouraging CF interim Phase 2 data support continued and expanded trial design 12-week safety and preliminary efficacy study in up to 20 CF participants planned to start H1 2026 Additional cost reductions planned in fourth quarter to extend cash runway Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the third quarter ended September 30, 2025, and provided corporate updates. "We were pleased to share the initi

    11/10/25 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter ended September 30, 2025 after the market close on Monday, November 10 and will also host a conference call and webcast at 4:30 pm Eastern Time on November 10, 2025. Arcturus Therapeutics Third Quarter 2025 Earnings Conference Call Monday, November 10, 2025, at 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS Webcast: Link A

    10/28/25 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

    Cystic fibrosis (ARCT-032) Phase 2 interim data from first nine participants to be presented in September Cystic fibrosis Phase 2 trial expected to complete enrollment by year end 2025 OTC deficiency (ARCT-810) Phase 3 trial design alignment with regulatory agencies expected H1 2026 Seasonal flu (ARCT-2138) showed positive Phase 1 results BARDA pandemic flu (ARCT-2304) Phase 1 results expected 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, tod

    8/11/25 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Leadership Updates

    Live Leadership Updates

    View All

    Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company's Board of Directors since June 2024. "Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate," said Joseph Payne, President & Chief Executive Officer of Arcturus. "We look forward to working with him as we enter a transformative yea

    2/4/25 8:30:00 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

    Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors. "Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and comm

    6/20/24 8:00:00 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Appoints John Markels, Ph.D. to its Board of Directors

    Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company's vaccine franchise Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Markels will provide strategic oversight to the C

    12/13/22 8:30:00 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

    SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

    11/8/24 3:17:24 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

    SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

    11/5/24 6:07:26 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

    SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

    4/5/24 12:18:33 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care